Acneiform rash

ADCC. Cetuximab is approved for treatment of metastatic colorectal cancer (CRC) and squamous cell carcinoma of the head and neck (SCCHN). Interestingly, an adverse event, acneiform rash seems to correlate with a better response to cetuximab, while there is no such correlation with expression levels of EGFR assessed by immunohistochemistry. Further side effects are rare infusion reactions and hypomagnesia. Two other anti-EGFR antibodies approved for clinical use are the fully human antibody panitumumab (Vectibix)... 

Cetuximab plus irinotecan Continue irinotecan as previously dosed, plus cetuximab 400 mg/m2 IV loading dose, then cetuximab 250 mg/m2 Asthenia, diarrhea, nausea, acneiform rash,... 

Cetuximab has modest activity in relapsed colorectal cancer as a single agent but is more effective with irinotecan and possibly oxaliplatin based regimens where a doubling of the response rate has been observed. There is some evidence that cetuximab may reverse irinotecan resistance. Toxic effects of cetuximab include hypersensitivity reactions, malaise, nausea, headache and an acneiform rash. 

Iodides should not be used alone since the normal gland will escape from iodide blockade in 2-8 weeks. Chronic use in pregnancy is not recommended because it crosses placenta and cause fetal goitre. Iodide treatment results in high intrathyroidal iodide content that can delay the onset of thioamide therapy or delay the use for radioactive iodine therapy for weeks if not months. Adverse effects include Hodism which is rare and reversible. The clinical symptoms are acneiform rash, sialadenitis, mucous membrane ulceration, conjuctivitis, rhinor-rhoea, metallic taste and rarely anaphylactoid reaction. 

Adverse reactions to iodine (iodism) are uncommon and in most cases reversible upon discontinuance. They include acneiform rash (similar to that of bromism), swollen salivary glands, mucous membrane ulcerations, conjunctivitis, rhinorrhea, drug fever, metallic taste, bleeding disorders and, rarely, anaphylactoid reactions. 

Asthenia, diarrhea, nausea, acneiform rash, vomiting... 

Different tjrpes of rash, including a case of acneiform rash, have been reported in patients taking itraconazole. In one case there were bloody bullae (SED-12, 680) (40-43). 

Skin rashes have been reported occasionally (29) these include an acneiform rash and urticaria. 

Iododerma, which is thought to be an allergic reaction, starts with an acneiform lesion, localized in the area of the sebaceous glands, which spreads to form verrucous granulomatous lesions (61,62). After discontinuation of iodide, the skin clears over a few weeks. In addition to this typical picture of iodide sensitivity, iodide can cause urticaria and erythema and even hemorrhagic rashes. In order to verify the etiology of the skin conditions in certain cases, sensitivity testing may be required, but is not without risk. 

Morbilliform, maculopapular, or urticarial rashes have been observed in up to 2% of patients (9). In one study, acneiform eruptions developed in only 11 cases (1.4%), including 0.5% of patients taking isoniazid, 1.5% of patients taking rifampicin, and 0.6% of patients taking ethambutol (36). 

Erlotinib (OSI-774, Epidermal growth factor receptor (EGER) tyrosine kinase Acneiform skin rash, diarrhea. Phase 1... 

C. Dermatologic effects include acneiform, pustular, or erythematous rashes. Up to 25% of patients are affected. 

Methotrexate An amino- Breast, head, neck, lung, Inhibits dihydro Rash acneiform papular Anaph low white cell count Types H, II (hemolytic anemia). 

---